Processa Pharmaceuticals Total Assets | PCSA

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Processa Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
7.81 M	3.23 M	5.79 M	8.62 M	26.5 M	25.2 M	10.9 M	13.2 M	2.98 M	3.24 K	104 K	2.54 M	2.94 M	3.88 M	5.31 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26.5 M	3.24 K	7.93 M

Quarterly Total Assets Processa Pharmaceuticals

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.52 M	7.58 M	8.18 M	4.81 M	3.23 M	4.94 M	7.6 M	-	5.79 M	8.08 M	10.1 M	12.4 M	8.62 M	18.6 M	21.7 M	24.3 M	26.5 M	29 M	31.1 M	33.3 M	25.2 M	25.2 M	25.2 M	25.2 M	10.9 M	10.9 M	10.9 M	10.9 M	12.5 M	12.5 M	12.5 M	12.5 M	2.98 M	2.98 M	2.98 M	2.98 M	2.36 M	3.24 K	3.24 K	3.24 K	104 K	104 K	104 K	104 K	2.55 M	2.54 M	2.54 M	2.54 M	2.94 M	2.94 M	2.94 M	2.94 M	3.88 M	3.88 M	3.88 M	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
33.3 M	3.24 K	9.5 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	2.05 B	-	-	-	Russia
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	816 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	24.6 M	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	2.35 B	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	480 M	$ 101.8	0.08 %	$ 6.62 B	USA
Rezolute RZLT	175 M	$ 4.4	0.88 %	$ 334 M	USA
Sana Biotechnology SANA	417 M	$ 3.45	0.77 %	$ 874 M	USA
Seer SEER	296 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	156 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	219 M	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	530 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	9.24 M	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	53 M	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	3.35 B	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	418 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	174 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	91 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	1.45 B	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	253 M	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	34.8 M	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	14.2 T	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	2.59 B	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	104 M	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	40.7 B	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	1.06 B	$ 55.74	0.58 %	$ 8.04 B	USA
Trevi Therapeutics TRVI	193 M	$ 16.82	1.17 %	$ 2.27 B	USA
Taysha Gene Therapies TSHA	343 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	29.9 M	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	200 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	7.88 B	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	68.9 M	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	404 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	213 M	-	-	$ 98.4 M	USA
NextCure NXTC	50.2 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	47.1 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	899 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	48.4 M	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	25.6 B	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	246 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	89.9 M	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	252 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	638 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	277 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	8.36 M	$ 4.28	0.86 %	$ 7.28 M	USA
XBiotech XBIT	150 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	14 M	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	633 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	384 M	$ 8.48	0.12 %	$ 1.36 B	USA